Projects per year
Abstract
The existing suite of therapies for bone diseases largely act to prevent further bone loss but fail to stimulate healthy bone formation and repair. We describe an endogenous osteopeptide (PEPITEM) with anabolic osteogenic activity, regulating bone remodeling in health and disease. PEPITEM acts directly on osteoblasts through NCAM-1 signaling to promote their maturation and formation of new bone, leading to enhanced trabecular bone growth and strength. Simultaneously, PEPITEM stimulates an inhibitory paracrine loop: promoting osteoblast release of the decoy receptor osteoprotegerin, which sequesters RANKL, thereby limiting osteoclast activity and bone resorption. In disease models, PEPITEM therapy halts osteoporosis-induced bone loss and arthritis-induced bone damage in mice and stimulates new bone formation in osteoblasts derived from patient samples. Thus, PEPITEM offers an alternative therapeutic option in the management of diseases with excessive bone loss, promoting an endogenous anabolic pathway to induce bone remodeling and redress the imbalance in bone turnover.
Original language | English |
---|---|
Article number | 101574 |
Number of pages | 17 |
Journal | Cell Reports Medicine |
Volume | 5 |
Issue number | 5 |
DOIs | |
Publication status | Published - 21 May 2024 |
Bibliographical note
Copyright © 2024 The Author(s). Published by Elsevier Inc.Keywords
- Animals
- Humans
- Osteoblasts/metabolism
- Osteogenesis/drug effects
- Mice
- Bone Resorption/pathology
- Anabolic Agents/pharmacology
- Bone Remodeling/drug effects
- Osteoporosis/pathology
- RANK Ligand/metabolism
- Osteoclasts/metabolism
- Bone Development/drug effects
- Osteoprotegerin/metabolism
- Female
- Signal Transduction/drug effects
- Peptides/pharmacology
- Male
- Mice, Inbred C57BL
- Bone and Bones/drug effects
Fingerprint
Dive into the research topics of 'Therapeutic avenues in bone repair: Harnessing an anabolic osteopeptide, PEPITEM, to boost bone growth and prevent bone loss'. Together they form a unique fingerprint.-
Rheumatoid Arthritis Centre for Excellence (RACE 2)
Filer, A. (Co-Investigator), Lord, J. (Co-Investigator), Scheel-Toellner, D. (Co-Investigator), Anderson, G. (Co-Investigator), Buckley, C. (Co-Investigator), Clark, A. (Co-Investigator), Falahee, M. (Co-Investigator) & Croft, A. (Principal Investigator)
1/04/19 → 30/09/25
Project: Research
-
The ageing bone - PEPITEM as a novel inducer of bone repair
McGettrick, H. (Principal Investigator)
BRITISH SOCIETY FOR RESEARCH AGEING
1/10/21 → 31/12/24
Project: Research
-
New therapeutic avenues in arthritis: exploring the role of PEPITEM in RA
Filer, A. (Co-Investigator), McGettrick, H. (Principal Investigator), Rainger, E. (Co-Investigator) & Raza, K. (Co-Investigator)
1/03/21 → 30/04/24
Project: Research Councils
-
WT TDF: New therapeutic avenues in bone repair
McGettrick, H. (Principal Investigator) & Naylor, A. (Co-Investigator)
1/04/20 → 31/12/21
Project: Research
-
Obesity-associated joint inflammation in patients with osteoarthritis: The role of long non coding RNAs
Jones, S. (Principal Investigator)
14/05/18 → 13/08/22
Project: Research
-
Type 14 C-type lectins link endothelial cells and bone remodelling in inflammatory arthiritis
Naylor, A. (Principal Investigator)
1/01/18 → 31/12/24
Project: Research
-
Are synovitis-associated IncRNAs central regulators of inflammatory pain in patients with knee OA: A route to identifying a novel analgesic drug for OA patients
Hardy, R. (Co-Investigator) & Jones, S. (Principal Investigator)
1/11/17 → 31/07/23
Project: Research